ArticleMolecular medicine (Cambridge, Mass.)2021
MiR-206 regulates the Th17/Treg ratio during osteoarthritis.
Article in Molecular medicine (Cambridge, Mass.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- A Systematic Review of miRNA and cfDNA as Potential Biomarkers for Liquid Biopsy in Myocarditis and Inflammatory Dilated Cardiomyopathy.Biomolecules · 2022Pooled it
- Trial
- Comparison of innate and adaptive immune responses to joint injury during the onset and progression of post-traumatic osteoarthritis in common murine models.Scientific reports · 2026Article
- Multimodal modulation of metal-based nanomaterials in osteoarthritis immunotherapy: current landscape and future paradigms.Frontiers in immunology · 2026Review
- Targeting subchondral osteoporosis in osteoarthritis: biomechanical crosstalk and the therapeutic rationale for inflammatory microenvironment remodeling.Frontiers in immunology · 2026Review
- "Gut-Joint Axis" Perspective on Immunometabolic Crosstalk in Osteoarthritis: A Narrative Review of Mechanistic Insights and Targeted Strategies.Journal of inflammation research · 2026Review
- Target Fibroblast-B cell crosstalk via MIF signaling drives pathogenic B cell differentiation and joint damage in knee osteoarthritis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- miRNAs and T cell-mediated Immune Response in Disease.The Yale journal of biology and medicine · 2025Review
- Adipose-derived mesenchymal stem cells combined with platelet-rich plasma are superior options for the treatment of osteoarthritis.Journal of orthopaedic surgery and research · 2025Article
- Immune cells differentiation in osteoarthritic cartilage damage: friends or foes?Frontiers in immunology · 2025Review
- Synovial mast cells and osteoarthritis: Current understandings and future perspectives.Heliyon · 2024Review
- Immunoengineering Biomaterials for Musculoskeletal Tissue Repair across Lifespan.Advanced materials (Deerfield Beach, Fla.) · 2024Review
- The role of microRNA-142a in Toxoplasma gondii infection-induced downregulation of Foxp3: implications for adverse pregnancy outcomes.BMC infectious diseases · 2024Article
- STUDY ON THE ROLE AND MECHANISM OF MICRORNA-650/WNT1 IN THE REPAIR OF ARTICULAR CARTILAGE INJURY.Acta ortopedica brasileira · 2024Article
- The role of Th/Treg immune cells in osteoarthritis.Frontiers in immunology · 2024Review
- Exploring the mechanism of action of Modified Simiao Powder in the treatment of osteoarthritis: anFrontiers in medicine · 2024Article
- Exosome-derived microRNAs: emerging players in vitiligo.Frontiers in immunology · 2024Review
- The Promotion of Humoral Immune Responses in Humans via SOCS1-Mediated Th2-Bias Following SARS-CoV-2 Vaccination.Vaccines · 2023Article
- Mesenchymal Stromal Cells-Derived Extracellular Vesicles as Potential Treatments for Osteoarthritis.Pharmaceutics · 2023Review
- Breast cancer tumor microenvironment affects Treg/IL-17-producing Treg/Th17 cell axis: Molecular and therapeutic perspectives.Molecular therapy oncolytics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe present study aimed to determine the functional role of miR-206 in T helper 17 (Th17)/regulatory T (Treg) cell differentiation during the development of osteoarthritis (OA).
methodsPatients with OA and healthy controls were recruited for investigating the association between miR-206 and Th17/Treg ratio. Transfection experiments were conducted in CD4
resultsHigh expression of miR-206 was positively correlated with peripheral Th17/Treg imbalance in patients with OA. The interactions between miR-206 and the 3' untranslated regions (3'-UTR) of suppressor of cytokine signaling-3 (SOCS3) and fork head transcriptional factor 3 (Foxp3) were confirmed by luciferase reporter assays. MiR-206 disturbed the Th17/Treg balance by targeting SOCS3 and Foxp3. In vivo assay demonstrated that antagomiR directed against miR-206 restored Th17/Treg balance during the development of OA.
conclusionMiR-206 contributed to the progression of OA by modulating Th17/Treg imbalance, suggesting that miR-206 inhibition might be a promising therapeutic strategy for the treatment of OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.